Mutation Combinations Database
Comprehensive guide to genetic mutation combinations in colorectal cancer, their clinical implications, and treatment recommendations.
Clinical Implications
Different biology. May retain anti-EGFR sensitivity.
Class 2/3 mutations behave differently.
Recommended
Avoid
Clinical Implications
FGFR inhibitors approved in other tumors. CRC trials ongoing.
FGFR2 fusions most actionable.
Recommended
Clinical Implications
May cause immunotherapy resistance. Watch for CRC data.
Better understood in lung cancer.
Recommended
Clinical Implications
Associated with poor prognosis and anti-EGFR resistance.
May emerge on anti-EGFR treatment.
Recommended
Avoid
About This Database
This database contains clinically relevant mutation combinations in colorectal cancer. Each combination includes:
- Genes involved - The genetic alterations present
- Prognosis - Expected outcome classification
- Prevalence - How common in CRC patients
- Recommended treatments - Evidence-based options
- Treatments to avoid - Known ineffective therapies
- Evidence level - Strength of supporting data
Actionable combinations have FDA-approved targeted therapies or strong clinical trial evidence. Always consult with your oncologist for personalized treatment decisions.